STA Pharmaceutical Co., Ltd., a WuXi AppTec subsidiary, has signed a supply agreement with the oncology-focused biopharmaceutical company, TESARO, Inc. for certain starting and intermediate materials for ZEJULA (Niraparib).

 

Under the five-year agreement, STA will provide certain starting and intermediate materials for the recently launched ZEJULA – an orally active and potent poly(ADP-ribose) polymerase (PARP) inhibitor for the treatment of ovarian cancer. ZEJULA was FDA-approved for epithelial ovarian, fallopian tube or primary peritoneal cancer on March 27th 2017, and is now available to patients in the U.S. This agreement follows a successful multiple-year development and clinical manufacturing arrangement with TESARO.

 

A Phase III trial demonstrated that ZEJULA offers a clinically meaningful increase in progression-free survival (PFS) in women with recurrent ovarian cancer, regardless of BRCA mutation or biomarker status.

 

“We have been working with TESARO for a number of years, and we are honoured to be selected as a TESARO global supplies partner for this critical life-saving drug,” said Dr. Minzhang Chen, chief executive officer of STA Pharmaceutical. “STA is committed to helping our partners develop and commercialize innovative breakthrough drugs like ZEJULA via our state-of-the-art enabling platform. It has been an extremely successful partnership and we look forward to working alongside the TESARO team to expedite their development and commercial timelines.”